share_log

Phathom Pharmaceuticals Insiders Sold US$942k Of Shares Suggesting Hesitancy

Phathom Pharmaceuticals Insiders Sold US$942k Of Shares Suggesting Hesitancy

Phathom Pharmaceuticals內部人士賣出94.2萬美元的股票,表明有所猶豫
Simply Wall St ·  10/19 22:41

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) shareholders may have reason to be concerned, as several insiders sold their shares over the past year. When evaluating insider transactions, knowing whether insiders are buying is usually more beneficial than knowing whether they are selling, as the latter can be open to many interpretations. However, if numerous insiders are selling, shareholders should investigate more.

Phathom Pharmaceuticals公司(納斯達克:PHAT)的股東可能有理由感到擔憂,因爲過去一年有多名內部人士出售了他們的股票。在評估內部交易時,了解內部人士是否在買入通常比了解他們是否在賣出更有益,因爲後者可能會有很多解讀。不過,如果有很多內部人士在賣出,股東應該加以調查。

Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.

雖然我們不認爲股東應該簡單地跟隨內部交易,但完全忽略內部交易將是愚蠢的。

The Last 12 Months Of Insider Transactions At Phathom Pharmaceuticals

在Phathom Pharmaceuticals的內部交易中,過去12個月發生了多次內部交易。

The President, Terrie Curran, made the biggest insider sale in the last 12 months. That single transaction was for US$397k worth of shares at a price of US$11.72 each. That means that even when the share price was below the current price of US$16.08, an insider wanted to cash in some shares. When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. However, while insider selling is sometimes discouraging, it's only a weak signal. This single sale was just 17% of Terrie Curran's stake.

董事長Terrie Curran在過去12個月內進行了最大規模的內部銷售。那筆交易總價值爲39.7萬美元,每股價格爲11.72美元。這意味着,即使股價低於當前的16.08美元,一位內部人士仍想套現一些股票。當內部人士以低於當前價格出售股票時,這表明他們認爲較低價格是公平的。這讓我們想知道他們對(較高的)最近估值的看法。然而,儘管內部賣出有時會令人沮喪,它只是一個弱信號。這一次銷售僅佔Terrie Curran持股的17%。

All up, insiders sold more shares in Phathom Pharmaceuticals than they bought, over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

總的來說,過去一年內部人士在Phathom Pharmaceuticals出售的股票多於購買的股票。您可以在下方看到內部交易(按公司和個人分類)在過去12個月內的可視化描述。如果您點擊圖表,可以看到所有個體交易,包括股價、個人和日期!

big
NasdaqGS:PHAT Insider Trading Volume October 19th 2024
納斯達克GS:phathom pharmaceuticals 內部交易量,2024年10月19日

I will like Phathom Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

如果我看到一些大額內部買入交易,我會更喜歡phathom pharmaceuticals。在等待時,請查看這份免費的小盤股和被高估股票的名單,其中包括最近有相當多內部買入交易的股票。

Insider Ownership Of Phathom Pharmaceuticals

phathom pharmaceuticals內部持股情況

Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 3.7% of Phathom Pharmaceuticals shares, worth about US$41m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

許多投資者喜歡查看公司內部持股比例。通常,內部持股比例越高,內部人員越可能被激勵來爲長期發展打造公司。內部人員持有phathom pharmaceuticals股份的比例爲3.7%,價值約4100萬美元。 這一內部持股水平不錯,但尚未達到特別突出的水平。 這確實表明了一定程度上的一致性。

So What Does This Data Suggest About Phathom Pharmaceuticals Insiders?

這些數據對phathom pharmaceuticals內部人員有何啓示?

There haven't been any insider transactions in the last three months -- that doesn't mean much. We don't take much encouragement from the transactions by Phathom Pharmaceuticals insiders. But we do like the fact that insiders own a fair chunk of the company. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. At Simply Wall St, we've found that Phathom Pharmaceuticals has 3 warning signs (1 doesn't sit too well with us!) that deserve your attention before going any further with your analysis.

過去三個月內沒有內部交易——這並不代表太多。phathom pharmaceuticals內部人員的交易並未給予我們太多鼓舞。 但我們確實喜歡內部人員持有公司的相當一部分股份這一事實。 因此,這些內部交易可以幫助我們建立關於股票的主題,但了解這家公司面臨的風險也是值得的。在Simply Wall St上,我們發現phathom pharmaceuticals有3個警示信號(其中一個對我們來說不太令人滿意!)在進行進一步分析之前,這些應該引起您的注意。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果您想查看另一家公司的信息-一家潛在具有優秀財務狀況的公司-請不要錯過這個帶有高股權回報率和低債務的有趣公司免費列表。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論